Priority Filings Sample Clauses
The Priority Filings clause establishes the order in which documents or interests are officially recorded or registered, ensuring that certain filings take precedence over others. In practice, this clause may specify that a lender’s security interest must be filed before any subsequent claims, or that certain documents are to be registered with government authorities ahead of others to secure their legal standing. Its core function is to prevent disputes over competing claims by clearly defining which party’s rights are recognized first, thereby reducing legal uncertainty and protecting the interests of the party with priority.
Priority Filings. When a MTI Invention or Joint Invention has been made which may reasonably be considered to be patentable, MTI promptly shall file a United States priority patent application, and, in the case of a Joint Invention, shall assign such patent application jointly to Sankyo and MTI. When a Sankyo Invention has been made which may reasonably be considered to be patentable, Sankyo promptly shall file a Japanese priority patent application. MTI shall give Sankyo an opportunity to review the text of an application for a Joint Invention before filing, and shall supply Sankyo with a copy of the application as filed, together with a note of its filing date and serial number.
Priority Filings. When a Versicor Invention or a Joint Invention has been made which may reasonably be considered to be patentable and as to which Novartis is licensed under this Agreement, a priority patent application shall be filed by Versicor in the United States as soon as reasonably possible with a patent counsel selected by Novartis in the case of a Joint Invention. Versicor shall give Novartis an opportunity to review the text of any application for a Joint Invention before filing and shall supply Novartis with a copy of the application as filed, together with a note of its filing date and serial number. The costs of such priority filings for Versicor Inventions and Joint Inventions shall be borne by Novartis.
Priority Filings. When an Invention has been made which may reasonably be considered to be patentable, (a) ▇▇▇▇▇▇▇-▇▇▇▇▇ in the case of (i) all ▇▇▇▇▇▇▇-▇▇▇▇▇ Inventions, (ii) those Joint Inventions that constitute composition of matter and related use inventions (including without limitation Joint Inventions that constitute Program Antibodies, Products or related Materials necessary solely for the production or use of Program Antibodies or Products or the use of Program Antibodies or Products), and (iii) those Ixsys Inventions that constitute BR96 Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies or Products containing BR96 Antibodies, human or humanized BR96 antibodies, L6 Antibodies, human or humanized L6 antibodies, or related Materials necessary solely for the production or use of any of the foregoing or the use of Program Antibodies or Products, and (b) Ixsys in the case of all other Joint Inventions and all other Ixsys Inventions, shall file a priority patent application in the United States as soon as reasonably practicable. The party filing the application shall give the other party an opportunity to review the text of the application before filing, shall control the preparation and filing of such application, and shall supply the other party with a copy of the application as filed, together with notice of its filing date and serial number.
Priority Filings. When an Invention or Joint Invention has been made under the Research Program which may reasonably be considered to be patentable, a priority patent application shall be filed as soon as reasonably possible. If a Joint Invention has been made under the Research Program, the parties shall designate mutually acceptable independent patent counsel which shall file such application which shall be in the name of both Parties. The Party filing the application with respect to an Invention or Joint Invention made under the Research Program shall give the other Party an opportunity to review the text of the application before filing, and in good faith shall consider and incorporate the reasonable requests of the other Party. The Party filing the application with respect to any Invention or Joint Invention made under the Research Program shall supply the other Party with a copy of the application as filed, together with notice of its filing date and serial number.
Priority Filings. When a Gensia Sicor Invention or Joint Invention ---------------- has been made which may reasonably be considered to be patentable, Gensia Sicor promptly shall file a United States priority patent application, and, in the case of a Joint Invention, shall assign such patent application jointly to Sankyo and Gensia Sicor. When a Sankyo Invention has been made which may reasonably be considered to be patentable, Sankyo promptly shall file a Japanese priority patent application. Gensia Sicor shall give Sankyo an opportunity to review the text of an application for a Joint Invention before filing, and shall supply Sankyo with a copy of the application as filed, together with a note of its filing date and serial number.
Priority Filings. When an Invention or Joint Invention has been made under the RESEARCH PROGRAM which may reasonably be considered to be patentable, a priority patent application shall be filed as soon as reasonably possible. As used in this Agreement, a "priority patent application" means a patent application that establishes a filing date under the Convention of Paris for the Protection of Industrial Property. If a Joint Invention has been made under the RESEARCH PROGRAM, SB shall have the first right, using in-house or outside legal counsel selected at SB's sole discretion, to prepare, file, prosecute, maintain and extend patent applications and patents concerning all such inventions and discoveries owned in whole by SB or jointly by SB and LIGAND in countries of SB's choice throughout the world with appropriate credit to LIGAND representatives, including the naming of such parties as inventors where appropriate and in accordance with the relevant legal requirements, for which SB shall bear the costs relating to such activities which occur at SB's request or direction. SB shall solicit the LRC's advice and review of the nature and text of such patent applications and important prosecution matters related thereto in reasonably sufficient time prior to filing thereof, and SB shall take into account the LRC's reasonable comments related thereto. If SB, prior or subsequent to filing certain patent applications on any inventions or discoveries which are owned in whole or in part by LIGAND, elects not to file, prosecute or maintain such patent applications or ensuing patents or certain claims encompassed by such patent applications or ensuing patents in any country of the TERRITORY, SB shall give LIGAND notice thereof within a reasonable period prior to allowing such patent applications or patents or such certain claims encompassed by such patent applications or patents to lapse or become abandoned or unenforceable, and LIGAND shall thereafter have the right, at its sole expense, to prepare, file, prosecute and maintain patent applications and patents or divisional applications related to such certain claims encompassed by such patent applications or patents concerning all such inventions and discoveries in countries of its choice throughout the world. The party filing the application with respect to an Invention or Joint Invention made under the RESEARCH PROGRAM shall give the other party an opportunity to review the text of the application before filing, and in good faith sh...
Priority Filings. When a LIGAND Invention, TAP Invention or Joint Invention has been made under the Research Program, such invention shall be promptly disclosed to the other party and the JRC as well as each party's respective patent counsel. The JRC shall consult with each party's respective patent counsel in its determination of whether such invention is a LIGAND, TAP, or Joint Invention. If the JRC and each party's respective patent counsel all agree on the determination of inventorship, such determination shall be conclusive. If, however, the JRC and the party's respective patent counsel cannot agree as to whether an invention is a LIGAND, TAP, or Joint Invention, the status of such an invention shall be determined pursuant to Article 20 of this Agreement. If a Joint Invention has been made under the Research Program, the JRC shall designate independent patent counsel that shall file such application, which shall be in the name of both parties as assignees or applicants as appropriate. The party or independent patent counsel filing the application with respect to a Joint Invention made under the Research Program shall give the other party an opportunity to review the text of the application before filing, and in good faith shall consider and incorporate the reasonable requests of the other party. The party or independent patent counsel filing the application with respect to any LIGAND or TAP Invention or Joint Invention made under the Research Program shall supply the other party with a copy of the application as filed, together with notice of its filing date and serial number. In the event that the JRC is no longer in existence and a determination regarding inventorship under this Section 13.2.1 is necessary, a designated representative of each party shall act in the place of the JRC under this Section 13.2.1.